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ACT 
An appreciation of the natural history of acquired valvular heart 
disease is a prerequisite to an understanding of how surgical 
intervention has altered the natural outlook. The prognosis for a 
patient with valvular heart disease treated medically is depen- 
dent on the stage of the disease at which he is first seen. 
Therefore, assessment )Cot" surgery requires evaluation of the 
pathophysiologic consequences that have resulted from the hemo- 
dynamic alterations. Survival statistics for patients een at the 
University of California Medical Center at San Francisco are 
presented and compared with the data of others. Stenotic lesions 
appear to have a poorer prognosis than chronic regurgitant 
lesions and generally wm~ant surgical intervention at an earlier 
functional stage of the disease. Howevo; valvular insujEciency 
produced acutely is poorly tolerated and many constfute a 
surgical emergency. 
The selection of patients with mitral or aortic valve disease 
for surgery obviously requires an appreciation of the natural 
history of valvular heart disease. One must weigh the expected 
surgical morbidity and mortality against he anticipated out- 
come of medical management alone. Therefore, one must know 
not only the early and late results of surgical procedures for 
various valvular lesions, but also the pathophysiologic conse- 
quences of valvular heart disease at various tages in its natural 
history. Simple awareness of average survival statistics is 
inadequate. For example, the prognosis of asymptomatic mih-al 
stenosis differs greatlyfi'om that of mitral stenosis that has led to 
severe pulmonary vascular disease with resultant puhnonary 
hypertension and cardiac decompensation. The purpose of this 
review is to examine the major valvular lesions in terms of theh" 
pathophysiologic consequences and their natural history in the 
absence of surgical intervention. 
Originally published in American Journal of Cardiology, February 1975. 
R£v /ew 
Advances in the evaluation and management of patients 
with valvular heart disease represent a true twentieth-century 
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success tory. The mortality and morbidity rates in the first half 
of this century associated with diseases of the aortic and mitral 
valves were little changed from those of the previous 2,000 
years. As recently as 1947 in the third edition of Heart Disease 
(1), Dr. Paul Dudley White indicated that "there is no specific 
treatment for mitral valve disease" and "there is no treatment 
for aortic valve disease." The remarkable progress that has been 
achieved in the last three decades, in terms of pathophysiologic 
understanding, diagnostic apabilities and corrective surgical 
and catheter-based techniques, has transformed aortic and 
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INTRODUCTION 
In this edition of the ]ournal, we release the ninth in a series of 
reviews of influential articles that have been previously pub- 
fished in ACC journals, including the Amoqcan Jommal of Cardi- 
ology (from 1958 to 1982) andJACC (from 1983 to the present). 
The publication of these articles is only one aspect of the ACC's 
50th anniversary commemoration, which highlights 50 years of 
leadership in cardiovascular care and education. The articles are 
intended to encourage r flection on the remarkable progress made 
in cardiovascular medicine over time, as well as to acknowledge the 
amazing prescience of some early investigators in anticipating and, 
in many cases, later guiding developments in their field. 
The working group responsible for selecting these articles and 
asking reviewers to write editorials olicited suggestions from 
the ACC's clinical committees and individiml members. 
The group achieved consensus fairly easily, including whom the 
group should ask to prepare the accompanying editorials. We 
initially drew up a list of 14 general areas to cover in this series, 
but later found that there are several major areas of modern 
cardiology, prominently molecular cardiology, in which the truly 
landmark articles have, ,alas, not yet been published in JACC. 
Therefore, the working group decided not to categorize by subject, 
but instead, to concentrate on the most important articles. 
The working group, a task force of the Subcommittee for the 
Commemoration f the ACC 50th Anniversary, owes a great 
deal to Ms. May A. Roustom and the efficient and tireless staff 
at Heart House for facilitating this project. We also wish to 
thank all who suggested articles and, most important, the 
authors who prepared reviews for their willingness to contribute 
their time and wisdom. 
Influential Articles in JACC Working Group 
Sharon A. Hunt, M.D., F.A.C.C. 
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mitral valve disease from incurable ailments to conditions that 
,are now recognized, characterized and treated routinely by 
c~rdiovascular physicians and surgeons, often providing pa- 
tients with the promise of a normal ifespan and quality of life. 
Dr. Elliott Rapaport's report (2) describing the natural 
history of aortic and mitral valve disease, highlighted in this 
historical review, was pubfished in 1975, on the threshold of 
these advances, at a critical transition point in the evolution 
of treatment of valvular heart disease. In the years preceding 
Dr. Rapaport's report, the only tools available to evaluate 
t~atients and characterize the severity of heart valve disease, 
and hence the only criteria that could be used to describe 
their natural history, consisted of symptoms, physical exam- 
mation, the electrocardiogram, chest X-ray film and, in very 
~elected patients, angiographic and hemodynamic measure- 
ments. At that time, surgical treatment was also at a turning 
point. The earliest model prosthetic ball valves had been 
Hnplanted for roughly 10 years, and the era ofbioprosthetic 
valves had just begun. The enormous progress in the quarter 
century since Dr. Rapaport's report includes the apprecia- 
tion of the importance of ventricular function in determin- 
ing natural history and outcome; the development of 
M-mode and two-dimensional echocardiography to assess 
valve pathology, chamber size and ventricular function; 
Doppler echocardiography to evaluate the severity of ste- 
~aotic and regurgitant lesions and pulmonary artery pres- 
sures; radionuclide ventriculography to assess ventricular 
function at rest and with exercise; percutaneous mitral 
balloon valvotomy as an effective treatment for mitral 
~tenosis; use of blood cardioplegia nd retrograde delivery of 
c~trdioplegia for intraoperative myocardial protection; bileaf- 
let mechanical valves; stentless bioprosthetic valves, ho- 
naograft valves and autograft valves for aortic valve replace- 
ment; mitral valve repair and chordal sparing mitral valve 
replacement to maintain integrity of the mitral apparatus in 
patients with mitral regurgitation; and combined valve 
replacement/repair nd coronary artery bypass graft surgery 
in patients with concomitant coronary artery and valvular heart 
disease. In reviewing the previous natural history data leading 
up to his own natural history study, Dr. Rapaport's paper also 
cpresents an important link between the presurgical era of the 
first half of this century, when there was no effective treatment 
for aortic or mitral valve disease, and the current era. 
A number of Dr. Rapaport's many insights (2) hold true 
today. These include the long latent period for both stenotic 
and regurgitant lesions before the onset of symptoms; the 
inexorable decline in survival once symptoms develop 
(which is most aggressive in patients with aortic stenosis); 
the poor outcome of patients with acute aortic or mitral 
regurgitation treated medically and the need to consider 
urgent surgery; and the differences in left ventricular wall 
stress and the resulting hypertrophic response between 
patients with chronic aortic regurgitation and those with 
chronic mitral regurgitation. However, several other aspects 
of Dr. Rapaport's discussion are now less applicable because 
of the aging of the population, changes in etiology of valve 
disease in the developed countries of the world and, impor- 
tantly, advances in diagnostic and surgical techniques. For 
example, the predominant cause of aortic stenosis in the 
U.S. is now degenerative calcific disease in middle-aged and 
elderly patients rather than congenital bicuspid disease (3), 
and aortic regurgitation also arises more frequently from a 
degenerative process than from congenital defects (4). Sim- 
ilarly, the predominant cause of mitral regurgitation is now 
mitral valve prolapse rather than rheumatic heart disease (4). 
Although rheumatic heart disease continues to be the cause 
of virtually all cases of mitral stenosis in adults, its natural 
course in the U.S. and Canada is now less virulent than it 
was in the early decades of this century; it is now milder and 
more delayed (5). It is not uncommon for symptoms of 
mitral stenosis to first present in middle age, and up to 
one-third of patients undergoing mitral balloon valvotomy 
are older than age 65 years (6). In contrast, in the presurgical 
era, the average age at death was 48 years (7), as noted by 
Dr. Rapaport. 
In addition to the evolution in etiology and natural 
history, data that are now acquired routinely to characterize 
virtually every patient with valvular heart disease were not 
available in 1975. As a result, a different perspective on the 
natural history of valvular heart disease has emerged over the 
25 years since publication of Dr. Rapaport's article. 
It is now apparent hat for any valve lesion, survival is 
influenced importantly by age, severity of symptoms, sever- 
ity of the valvular lesion itself, left or right ventricular 
systolic function and the presence or absence of concomitant 
coronary artery disease (4). Additional factors include atrial 
fibrillation and pulmonary hypertension in mitral valve 
disease, degree of left ventricular dilation in mitral or aortic 
regurgitation and severity of left ventricular hypertrophy in 
aortic stenosis or regurgitation (4). Although there are high- 
risk subgroups of patients with aortic or mitral valve disease 
in the current era in whom the natural history without 
surgical intervention approaches the ominous urvival curves 
reported in Dr. Rapaport's eries, this is clearly not the case 
for asymptomatic patients with normal eft and right ven- 
tricular size and function. 
In addition to the refinement of noninvasive methods for 
effective risk stratification and identification of patients, 
symptomatic and asymptomatic, who progress into higher risk 
subgroups, urgical intervention has also evolved ramatically 
in the last quarter century. Rather than operating only on the 
sickest patients with the most advanced forms of valvular heart 
disease, in whom the high short-term and long-term risks of 
the operation could be justified, valve replacement or repair is 
now safely performed at much earlier stages of the natural 
course of the disease process, often in asymptomafic patients, 
with excellent long-term results. Early intervention combined 
with advances in surgery have completely transformed the 
outlook of patients with aortic or mitral valve disease, com- 
pared to that depicted 25 years ago. 
Nonetheless, one of the most fundamental aspects of 
medical decision making in patients with aortic and mitral 
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valve disease has not changed.since 1975. Valve replacement 
or repair is still not a curative process, and patients who have 
undergone operation have replaced one set of  problematic 
and serious conditions with another (8). The goal is to 
operate late enough in the natural course to justify the risks 
of  intervention, but early enough to prevent irreversible 
ventricular dysfunction, pulmonary hypertension or chronic 
arrhythmias, or a combination of these complications. 
Although the balance between the risks of  the natural course 
of  the disease and the risks of  surgery now often favors early 
intervention, one must continue to weigh the anticipated early 
and late outcome of surgical procedures against he expected 
outcome of medical management alone (2). This decision 
requires both objective data and sound clinical judgment. This 
lesson from Dr. Rapaport still holds very true today. 
Reprint requests and correspondence: Dr. Robert O. Bonow, 
Division of Cardiology, Northwestern University Medical School, 
250 East Superior Street, Suite 524, Chicago, Illinois 60611. 
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